Pip6a – Immunology – Antigens/Epitotes/Pools/Librairies

Pip6a is part of a novel series of transduction peptides termed Pips (PNA/PMO internalisation peptides). Pip peptides were designed around an original R6-penetratin cell penetrating peptide (CPP) and are able to transport PNA/PMO molecules across cell membranes. Pip peptides can be covalently conjugated to PNAs/PMOs to deliver them to a variety of adult tissues, including liver, kidney, skeletal muscle, diaphragm, and heart. Due to its ability to target the heart, pip6a has important implications for the development of therapeutic antisense oligonucleotide therapy using PMOs for diseases such as Duchenne muscular dystrophy (DMD). DMD causes progressive muscle weakening and often results in cardiac failure and death. Pip6a has also been studied for delivery of antisense oligonucleotide therapy in spinal muscular atrophy (SMA).

Technical specification

Price